Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
NCT05917587Phase 1Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of liquid metformin (Aspargo Labs) in gestational diabetes mellitus (GDM) (2 arms). Primary endpoints: Blood flow response to acetylcholine at 12 weeks and Blood flow response to insulin at 12 weeks. Started Sep 2024; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT05917587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917587.